Screener
Aclaris Therapeutics ACRS Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 79.5%-6.3pp | 76.3%-9.7pp | 73.3%-11.8pp | 85.6%-4.0pp | 85.8%-4.8pp | |
| Operating margin | -1,050.2%-177pp | -961.9%-168pp | -975.9%-218pp | -973.9%-803pp | -873.4%-663pp | |
| Net margin | -921.5%-119pp | -832.6%-100pp | -829.6%-124pp | -900%-763pp | -802%-619pp | |
| Returns | ||||||
| Return on equity | -59.1%+42.3pp | -48.4%+42.6pp | -50.2%+34.3pp | -113.2%-87.4pp | -101.4%-64.0pp | |
| Return on invested capital | -79.9%+51.9pp | -69%+55.9pp | -69.8%+41.8pp | -168.2%-123pp | -131.8%-80.9pp | |
| Efficiency | ||||||
| Asset turnover | 0×-0.1× | 0×-0.1× | 0×0.0× | 0.1×0.0× | 0.1×-0.1× | |
| Liquidity | ||||||
| Current ratio | 3.5×-0.4× | 4×-1.0× | 3.4×-0.6× | 3.9×-3.1× | 3.9×-3.6× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $0.87-18.8% | $1.12-5.3% | $0.84-58.2% | $0.98-46.3% | $1.07-42.7% | |
| Valuation | ||||||
| Market capitalization | $868.56M+389% | $454.08M+174% | $326.12M+22.9% | $205.83M+151% | $164.59M+110% | |
| Price / sales | 105.7×+95.1× | 54.3×+45.0× | 41.7×+27.5× | 13.1×+10.0× | 9.8×+7.4× | |
| Price / book | 7×+5.6× | 3.2×+2.0× | 3.2×+1.5× | 1.7×+1.1× | 1.2×+0.7× |
FAQ
- What are Aclaris Therapeutics's profit margins?
- Aclaris Therapeutics (ACRS) runs a 79.5% gross margin and a -1050.2% operating margin, with a -921.5% net margin.
- Where do Aclaris Therapeutics's ratios come from?
- Every ratio is computed from Aclaris Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
